Aliases & Classifications for Peanut Allergy

MalaCards integrated aliases for Peanut Allergy:

Name: Peanut Allergy 12 15
Allergy to Peanuts 12 73
Peanut Allergic Reaction 12
Peanut Hypersensitivity 44
Allergies Peanut 55

Classifications:



External Ids:

Disease Ontology 12 DOID:4378
MeSH 44 D021183
SNOMED-CT 68 213021008 91935009
UMLS 73 C0559470

Summaries for Peanut Allergy

Disease Ontology : 12 A food allergy that is an allergy or hypersensitivity to dietary substances from peanuts causing an overreaction of the immune system which in a small percentage of people may lead to severe physical symptoms.

MalaCards based summary : Peanut Allergy, also known as allergy to peanuts, is related to esophagitis, eosinophilic, 1 and food allergy. An important gene associated with Peanut Allergy is FLG (Filaggrin), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Nicotine and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and t cells, and related phenotypes are immune system and respiratory system

Wikipedia : 76 Peanut allergy is a type of food allergy to peanuts. It is different from tree nut allergies. Physical... more...

Related Diseases for Peanut Allergy

Diseases related to Peanut Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 esophagitis, eosinophilic, 1 30.4 FLG IL13
2 food allergy 29.8 FLG IFNG IL10 IL13
3 dermatitis 29.0 CCL22 FLG IFNG IGHE IL13
4 dermatitis, atopic 28.2 CCL22 FLG IFNG IGHE IL10 IL13
5 asthma 27.3 CCL22 FLG HLA-DQB1 HLA-DRB1 IFNG IGHE
6 limbic encephalitis with lgi1 antibodies 10.8 HLA-DQB1 HLA-DRB1
7 exercise-induced anaphylaxis 10.8 FLG IGHE
8 refractory celiac disease 10.7 HLA-DQB1 IFNG
9 metal allergy 10.7 HLA-DQB1 HLA-DRB1
10 berylliosis 10.7 HLA-DRB1 IFNG
11 focal epithelial hyperplasia 10.7 HLA-DQB1 HLA-DRB1
12 hypersomnia 10.7 HLA-DQB1 HLA-DRB1
13 lichen planopilaris 10.7 HLA-DQB1 HLA-DRB1
14 eczema herpeticum 10.7 FLG IFNG
15 type ii mixed cryoglobulinemia 10.7 HLA-DQB1 HLA-DRB1
16 staphylococcal toxic shock syndrome 10.7 IFNG IGHE
17 beryllium disease 10.7 HLA-DQB1 HLA-DRB1
18 recurrent respiratory papillomatosis 10.7 HLA-DQB1 HLA-DRB1
19 autoimmune pancreatitis 10.7 HLA-DQB1 HLA-DRB1
20 eosinophilia-myalgia syndrome 10.7 HLA-DRB1 IFNG
21 pityriasis rosea 10.7 HLA-DQB1 HLA-DRB1
22 lichen sclerosus 10.7 HLA-DQB1 HLA-DRB1
23 whipple disease 10.7 HLA-DQB1 HLA-DRB1
24 african tick-bite fever 10.6 IFNG IL13
25 cytomegalovirus retinitis 10.6 HLA-DQB1 IFNG
26 pediatric multiple sclerosis 10.6 HLA-DQB1 HLA-DRB1
27 microscopic colitis 10.6 HLA-DRB1 IFNG
28 osteonecrosis of the jaw 10.6 HLA-DQB1 HLA-DRB1
29 penicillin allergy 10.6 IFNG IL13
30 hyperlucent lung 10.6 IFNG IL10
31 strongyloidiasis 10.6 IFNG IL13
32 histoplasmosis 10.6 HLA-DRB1 IFNG
33 juvenile myasthenia gravis 10.6 HLA-DRB1 IL10
34 sporotrichosis 10.6 IFNG IL10
35 baylisascariasis 10.6 IFNG IL10
36 eosinophilic fasciitis 10.6 AHR IFNG
37 urinary schistosomiasis 10.6 IFNG IL13
38 microscopic polyangiitis 10.6 HLA-DRB1 IL10
39 chronic graft versus host disease 10.5 IFNG IL10
40 idiopathic achalasia 10.5 HLA-DQB1 IL10
41 pericardial tuberculosis 10.5 IFNG IL10
42 actinic prurigo 10.5 HLA-DRB1 IL13
43 tuberculoid leprosy 10.5 IFNG IL10
44 clonorchiasis 10.5 IFNG IL10
45 hyper ige syndrome 10.5 IFNG IGHE
46 buruli ulcer 10.5 IFNG IL10
47 chronic active epstein-barr virus infection 10.5 IFNG IL10
48 ascaridiasis 10.5 IL10 IL13
49 multicentric castleman disease 10.5 IFNG IL10
50 oligoarticular juvenile idiopathic arthritis 10.5 HLA-DQB1 HLA-DRB1

Graphical network of the top 20 diseases related to Peanut Allergy:



Diseases related to Peanut Allergy

Symptoms & Phenotypes for Peanut Allergy

MGI Mouse Phenotypes related to Peanut Allergy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.56 AHR CCL22 CD14 CXCL10 HLA-DQB1 IFNG
2 respiratory system MP:0005388 9.1 AHR CD14 HLA-DQB1 IFNG IL10 IL13

Drugs & Therapeutics for Peanut Allergy

Drugs for Peanut Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Progesterone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 57-83-0 5994
3 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable
4 Progestins Phase 4,Phase 2,Not Applicable
5 Central Nervous System Stimulants Phase 4
6 Cholinergic Agents Phase 4
7 Nicotinic Agonists Phase 4
8 Hormone Antagonists Phase 4,Phase 2,Not Applicable
9 Hormones Phase 4,Phase 2,Not Applicable
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Not Applicable
12 Autonomic Agents Phase 4,Not Applicable
13 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
14 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
15 Vaccines Phase 3,Phase 1
16 Immunoglobulin E Phase 3,Phase 1,Phase 2,Not Applicable
17
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
18
Ketotifen Approved Phase 2 34580-14-8, 34580-13-7 3827
19
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
20
Glycerol Approved, Investigational Phase 1, Phase 2,Phase 2 56-81-5 753
21 Estradiol valerate Approved, Investigational, Vet_approved Phase 2 979-32-8
22
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
23
Polyestradiol phosphate Approved Phase 2 28014-46-2
24
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
25 tannic acid Approved, Nutraceutical Phase 1, Phase 2
26
Histamine Phosphate Phase 2 51-74-1 65513
27 Respiratory System Agents Phase 2,Phase 1,Not Applicable
28 Histamine Antagonists Phase 2
29 Histamine H1 Antagonists Phase 2
30 Dermatologic Agents Phase 2
31 Anti-Allergic Agents Phase 2,Phase 1
32 Anti-Asthmatic Agents Phase 2,Phase 1,Not Applicable
33 Antipruritics Phase 2
34 Pharmaceutical Solutions Phase 2,Phase 1,Not Applicable
35 Protective Agents Phase 1, Phase 2,Phase 2,Not Applicable
36 Contraceptive Agents Phase 2
37 Estradiol 17 beta-cypionate Phase 2
38 Estradiol 3-benzoate Phase 2
39 Immune Sera Phase 2
40 Estrogens Phase 2
41
Phenol Approved, Experimental Phase 1 108-95-2 996
42
Nitric Oxide Approved Not Applicable 10102-43-9 145068 160954
43 English walnut Approved, Nutraceutical ,Not Applicable
44 Chelating Agents
45 Proton Pump Inhibitors Not Applicable
46 Caseins
47 Vasodilator Agents Not Applicable
48 Endothelium-Dependent Relaxing Factors Not Applicable
49 Antioxidants Not Applicable
50 Bronchodilator Agents Not Applicable

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Recruiting NCT01966640 Phase 4
2 Progesterone and Brain Imaging Study Recruiting NCT01954966 Phase 4 Progesterone;Placebo
3 Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers Unknown status NCT02046083 Phase 2, Phase 3 arachid
4 Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy Completed NCT02636699 Phase 3
5 PALISADE Follow-on Study (ARC004) Recruiting NCT02993107 Phase 3
6 Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Active, not recruiting NCT02635776 Phase 3
7 Safety Study of Viaskin Peanut to Treat Peanut Allergy Active, not recruiting NCT02916446 Phase 3
8 ARTEMIS Peanut Allergy In Children Active, not recruiting NCT03201003 Phase 3
9 Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Active, not recruiting NCT03126227 Phase 3
10 Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age Active, not recruiting NCT03211247 Phase 3
11 Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children Active, not recruiting NCT03013517 Phase 3 Viaskin Peanut 250µg
12 Long-term Safety Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) Enrolling by invitation NCT03292484 Phase 3
13 AR101 Real-World Open-Label Extension Study Enrolling by invitation NCT03337542 Phase 3
14 Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization Unknown status NCT01625715 Phase 2 Ketotifen
15 Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy Unknown status NCT02402231 Phase 2 Omalizumab
16 The Effect of Extrinsic Factors on Food Allergy Unknown status NCT01429896 Phase 2
17 Therapeutic Effect of Chinese Herbal Medicine on Food Allergy Unknown status NCT00602160 Phase 2 FAHF-2 (TM)
18 Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy Completed NCT02920021 Phase 2 ANB020;Placebo
19 Oral Immunotherapy (OIT) for Peanut Allergy Completed NCT00815035 Phase 2 Peanut OIT;Placebo
20 Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy Completed NCT01675882 Phase 2
21 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Completed NCT01084174 Phase 1, Phase 2 Peanut powder;Peanut extract;Placebo extract;Placebo powder
22 Oral Immunotherapy for Peanut Allergy (PMIT) Completed NCT00597675 Phase 2
23 Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy Completed NCT00932282 Phase 1, Phase 2 Peanut Oral Immunotherapy;Omalizumab
24 Epicutaneous Immunotherapy in Peanut Allergy in Children Completed NCT01197053 Phase 2
25 Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study Completed NCT00932828 Phase 2 Peanut oral immunotherapy
26 Omalizumab in the Treatment of Peanut Allergy Completed NCT00949078 Phase 2 omalizumab
27 Xolair Enhances Oral Desensitization in Peanut Allergic Patients Completed NCT01290913 Phase 1, Phase 2 Omalizumab
28 A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial Completed NCT00580606 Phase 1, Phase 2 Glycerinated peanut allergenic extract;Placebo for peanut extract (glycerin)
29 Persistence of Oral Tolerance to Peanut Completed NCT01366846 Phase 2
30 Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Completed NCT01955109 Phase 2
31 Promoting Tolerance to Peanut in High-Risk Children Completed NCT00329784 Phase 2
32 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT Completed NCT01987817 Phase 2
33 Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using (CPNA) Peanut OIT Safety Follow-On Study Completed NCT02198664 Phase 2
34 A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g Completed NCT00382148 Phase 2 omalizumab
35 Mechanisms of Desensitization During Peanut Oral Immunotherapy Completed NCT01814241 Phase 2 Open label peanut OIT
36 A Study of Sublingual Immunotherapy in Peanut-allergic Children Completed NCT00597727 Phase 2 Peanut SLIT;Placebo SLIT
37 Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women Recruiting NCT03018366 Phase 2 17beta Estradiol;Transdermal placebo patch;Progesterone;Placebo Pill
38 Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study Active, not recruiting NCT02149719 Phase 2
39 Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Active, not recruiting NCT01373242 Phase 1, Phase 2 Liquid peanut extract (Peanut SLIT)
40 The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery Active, not recruiting NCT02103270 Phase 2 Peanut Protein 4,000mg;Oat Flour;Peanut Protein 300 mg
41 Salvage Peanut Oral Immunotherapy Study Active, not recruiting NCT03251508 Phase 1, Phase 2 Peanut OIT
42 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Active, not recruiting NCT01904604 Phase 2
43 Peanut Oral Immunotherapy in Children Active, not recruiting NCT01867671 Phase 2
44 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial Active, not recruiting NCT01781637 Phase 1, Phase 2 Omalizumab;placebo
45 Tolerance Following Peanut Oral Immunotherapy Active, not recruiting NCT01750879 Phase 1, Phase 2 Peanut Flour;Oat Flour
46 FARE Peanut SLIT and Early Tolerance Induction Active, not recruiting NCT02304991 Phase 2 Liquid Peanut Extract;Placebo Glycerin SLIT
47 The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy Terminated NCT01897077 Phase 1, Phase 2 Peanut Dissolving Film
48 Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults Terminated NCT01274429 Phase 1, Phase 2 Peanut flour
49 A Safety and Efficacy Study of Xolair in Peanut Allergy Terminated NCT00086606 Phase 2 Xolair (omalizumab)
50 Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy Withdrawn NCT01451450 Phase 2 QGE031;Placebo

Search NIH Clinical Center for Peanut Allergy

Cochrane evidence based reviews: peanut hypersensitivity

Genetic Tests for Peanut Allergy

Anatomical Context for Peanut Allergy

MalaCards organs/tissues related to Peanut Allergy:

41
Testes, Brain, T Cells, Skin

Publications for Peanut Allergy

Articles related to Peanut Allergy:

(show top 50) (show all 135)
# Title Authors Year
1
FDA-approved peanut allergy treatment: the first wave is about to crest. ( 29909055 )
2018
2
Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector T<sub>H</sub>2 subsets. ( 29408715 )
2018
3
Canadian genome-wide association study and meta-analysis confirm HLA as a risk factor for peanut allergy independent of asthma. ( 29325868 )
2018
4
A novel human mast cell activation test for peanut allergy. ( 29731128 )
2018
5
Potential Pitfalls in Applying Screening Criteria in Infants at Risk of Peanut Allergy. ( 29352591 )
2018
6
The Health and Economic Outcomes of Peanut Allergy Management Practices. ( 29751153 )
2018
7
A Mouse Model of Peanut Allergy Induced by Sensitization Through the Gastrointestinal Tract. ( 29956142 )
2018
8
Isotretinoin treatment and peanut allergy: a new case report and review of the literature. ( 29512201 )
2018
9
Peanut Allergy: An Epidemiologic Analysis of a Large Database. ( 29246346 )
2018
10
Nanoemulsion adjuvant-driven redirection of T<sub>H</sub>2 immunity inhibits allergic reactions in murine models of peanut allergy. ( 29655584 )
2018
11
Preventing Peanut Allergy. ( 29588872 )
2018
12
Challenge-confirmed peanut allergy in older patients: Performance of skin tests, specific immunoglobulin E, and ara h 2. ( 29508723 )
2018
13
Role of dendritic cells in peanut allergy. ( 29681186 )
2018
14
The role of environmental exposure to peanut and the development of peanut allergy. ( 29508711 )
2018
15
Should Younger Siblings of Peanut Allergic Children Be Screened for Peanut Allergy? ( 29397371 )
2018
16
Hepatic Mitochondrial Dysfunction and Immune Response in a Murine Model of Peanut Allergy. ( 29890625 )
2018
17
The importance of reducing risk in peanut allergy: Current and future therapies. ( 29289463 )
2018
18
Timely focus on breast-feeding in the peanut allergy debate. ( 29395368 )
2018
19
Peanut allergy reduction in high-risk pediatric patients. ( 29438186 )
2018
20
Preventing peanut allergy in infants: Follow the evidence. ( 29923919 )
2018
21
Understanding Caregiver Goals, Benefits, and Acceptable Risks of Peanut Allergy Therapies. ( 29940310 )
2018
22
Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan. ( 29603410 )
2018
23
Oral Immunotherapy in Japanese Children with Anaphylactic Peanut Allergy. ( 29339650 )
2018
24
Peanut Allergy Prevention. ( 29509854 )
2018
25
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. ( 29092786 )
2017
26
Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: The BAMSE population-based birth cohort. ( 28192142 )
2017
27
Genome-wide association study and meta-analysis in multiple populations identifies new loci for peanut allergy and establishes C11orf30/EMSY as a genetic risk factor for food allergy. ( 29030101 )
2017
28
Effect of endotoxin and alum adjuvant vaccine on peanut allergy. ( 28927819 )
2017
29
Allergen specificity of early peanut consumption and effect on development of allergic disease in the Learning Early About Peanut Allergy study cohort. ( 29097103 )
2017
30
Academy Approves NIAID Addendum Guidelines for the Prevention of Peanut Allergy. ( 28449792 )
2017
31
Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. ( 28065278 )
2017
32
Determination of Crucial Immunogenic Epitopes in Major Peanut Allergy Protein, Ara h2, via Novel Nanoallergen Platform. ( 28638052 )
2017
33
Re: &amp;quot;Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel&amp;quot;. ( 28390590 )
2017
34
Peanut allergy and isotretinoin: reply to McCarthy etA al. ( 28691221 )
2017
35
Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Summary of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel. ( 28449793 )
2017
36
A comparative study on basophil activation test, histamine release assay, and passive sensitization histamine release assay in the diagnosis of peanut allergy. ( 28686296 )
2017
37
Dose-time-response relationship in peanut allergy using a human model of passive cutaneous anaphylaxis. ( 28189335 )
2017
38
Economic evaluation of epinephrine auto-injectors for peanut allergy. ( 28634019 )
2017
39
Dose of allergens in a peanut snack (Bamba) associated with prevention of peanut allergy. ( 28709966 )
2017
40
Prediction of clinical peanut allergy status among children in Hamilton, Ontario using chart review data collected during 2012-2015. ( 28194191 )
2017
41
Peanut Allergen Threshold Study (PATS): Novel single-dose oral food challenge study to validate eliciting doses in children with peanut allergy. ( 28238744 )
2017
42
Evolution of Guidelines on Peanut Allergy and Peanut Introduction in Infants: A Review. ( 27820622 )
2017
43
US guidelines for the prevention of peanut allergy 2017. ( 29175880 )
2017
44
Indole-3-carbinol, a plant nutrient and AhR-Ligand precursor, supports oral tolerance against OVA and improves peanut allergy symptoms in mice. ( 28666018 )
2017
45
Updates on early peanut introduction and prevention of peanut allergy. ( 29479255 )
2017
46
Implementing Primary Prevention for Peanut Allergy at a Population Level. ( 28192569 )
2017
47
Guidelines for Children With Peanut Allergy. ( 28030748 )
2017
48
Skin Testing or sIgE Testing Is Necessary Before Early Introduction of Peanut for Prevention of Peanut Allergy: Pro-Con Debate. ( 28967547 )
2017
49
The Benefits of New Guidelines to Prevent Peanut Allergy. ( 28562280 )
2017
50
The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow's milk- and peanut allergy models. ( 29021893 )
2017

Variations for Peanut Allergy

Expression for Peanut Allergy

Search GEO for disease gene expression data for Peanut Allergy.

Pathways for Peanut Allergy

Pathways related to Peanut Allergy according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CCL22 CD14 CXCL10 HLA-DQB1 HLA-DRB1 IFNG
2
Show member pathways
13.03 CCL22 CXCL10 HLA-DQB1 HLA-DRB1 IFNG IGHE
3
Show member pathways
12.71 HLA-DQB1 HLA-DRB1 IFNG IL10 IL13
4
Show member pathways
12.61 CXCL10 HLA-DQB1 HLA-DRB1 IFNG IL13
5
Show member pathways
12.14 CXCL10 IFNG IL13
6 12.14 HLA-DQB1 HLA-DRB1 IFNG IL10
7
Show member pathways
12.08 HLA-DQB1 HLA-DRB1 IFNG IL10
8
Show member pathways
12.02 CD14 CXCL10 IFNG
9 12.02 CD14 HLA-DQB1 HLA-DRB1 IFNG IL10
10 11.98 CD14 HLA-DQB1 HLA-DRB1
11
Show member pathways
11.93 CCL22 IFNG IL10 IL13
12 11.85 CD14 IFNG IL10
13 11.79 CCL22 IGHE IL10 IL13
14 11.76 CD14 HLA-DQB1 HLA-DRB1
15 11.75 CD14 IFNG IL10
16 11.71 HLA-DQB1 HLA-DRB1 IFNG
17 11.61 CD14 IFNG IL10
18 11.61 AHR IFNG IL10 IL13
19
Show member pathways
11.52 AHR HLA-DQB1 HLA-DRB1 IFNG IL10 IL13
20 11.47 HLA-DQB1 HLA-DRB1 IL10
21 11.25 CCL22 CXCL10 IL10 IL13
22 11.18 IFNG IL10
23 11.18 CD14 IL10
24 11.18 AHR IFNG IL13
25 11.12 CCL22 IFNG IL10 IL13
26 11.1 HLA-DRB1 IFNG IL13
27 11.05 IFNG IL10 IL13
28 10.73 HLA-DRB1 IFNG IL10 IL13

GO Terms for Peanut Allergy

Cellular components related to Peanut Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 CCL22 CD14 CXCL10 IFNG IL10 IL13
2 endosome membrane GO:0010008 9.58 CD14 HLA-DQB1 HLA-DRB1
3 extracellular region GO:0005576 9.5 CCL22 CD14 CXCL10 IFNG IGHE IL10
4 clathrin-coated endocytic vesicle membrane GO:0030669 9.37 HLA-DQB1 HLA-DRB1
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.32 HLA-DQB1 HLA-DRB1
6 MHC class II protein complex GO:0042613 9.16 HLA-DQB1 HLA-DRB1
7 external side of plasma membrane GO:0009897 9.02 CD14 CXCL10 HLA-DRB1 IGHE IL13

Biological processes related to Peanut Allergy according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.72 CCL22 CXCL10 IFNG IL10 IL13
2 cellular response to lipopolysaccharide GO:0071222 9.7 CD14 CXCL10 IL10
3 response to lipopolysaccharide GO:0032496 9.67 CD14 CXCL10 IL10 IL13
4 response to virus GO:0009615 9.63 CCL22 CXCL10 IFNG
5 interferon-gamma-mediated signaling pathway GO:0060333 9.61 HLA-DQB1 HLA-DRB1 IFNG
6 negative regulation of endothelial cell apoptotic process GO:2000352 9.57 IL10 IL13
7 positive regulation of cytokine secretion GO:0050715 9.56 CD14 IL10
8 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 9.55 CXCL10 IL13
9 inflammatory response GO:0006954 9.55 CCL22 CD14 CXCL10 IL10 IL13
10 negative regulation of interferon-gamma production GO:0032689 9.54 HLA-DRB1 IL10
11 positive regulation of macrophage activation GO:0043032 9.51 IL10 IL13
12 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.49 HLA-DQB1 HLA-DRB1
13 response to molecule of bacterial origin GO:0002237 9.48 CD14 IL10
14 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.4 HLA-DQB1 HLA-DRB1
15 cytokine-mediated signaling pathway GO:0019221 9.35 CCL22 CXCL10 IGHE IL10 IL13
16 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.26 HLA-DQB1 HLA-DRB1
17 immune response GO:0006955 9.23 CCL22 CXCL10 HLA-DQB1 HLA-DRB1 IFNG IGHE

Molecular functions related to Peanut Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.16 HLA-DQB1 HLA-DRB1
2 cytokine activity GO:0005125 9.02 CCL22 CXCL10 IFNG IL10 IL13
3 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DRB1

Sources for Peanut Allergy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....